Literature DB >> 7710309

Rapid formation of clozapine in guinea-pigs and man following clozapine-N-oxide administration.

M W Jann1, Y W Lam, W H Chang.   

Abstract

Clozapine and its metabolite clozapine-N-oxide (0.5 mg/kg) were administered intraperitoneally to guinea-pigs. Significant amounts of clozapine were detected in plasma, liver, frontal cortex and caudate after clozapine-N-oxide administration. The amount of clozapine detected in plasma two hours post-administration of N-oxide was approximately 40% of the amount of clozapine after clozapine injection. Tissue concentrations of clozapine in liver, frontal cortex and caudate were greater than plasma concentrations. Clozapine concentrations were almost equivalent in the liver. Clozapine concentrations after N-oxide injection were approximately 40-50% lower compared to clozapine concentrations after clozapine administration in the frontal cortex and caudate. A single dose of clozapine-N-oxide was given to a schizophrenic patient. Clozapine plasma concentrations were detected after N-oxide administration. This study shows that clozapine is formed from its N-oxide metabolite and that a reversible metabolic pathway exists for clozapine and clozapine-N-oxide.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7710309

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  48 in total

1.  Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.

Authors:  Juan L Gomez; Jordi Bonaventura; Wojciech Lesniak; William B Mathews; Polina Sysa-Shah; Lionel A Rodriguez; Randall J Ellis; Christopher T Richie; Brandon K Harvey; Robert F Dannals; Martin G Pomper; Antonello Bonci; Michael Michaelides
Journal:  Science       Date:  2017-08-04       Impact factor: 47.728

2.  Endocannabinoid control of the insular-bed nucleus of the stria terminalis circuit regulates negative affective behavior associated with alcohol abstinence.

Authors:  Samuel W Centanni; Bridget D Morris; Joseph R Luchsinger; Gaurav Bedse; Tracy L Fetterly; Sachin Patel; Danny G Winder
Journal:  Neuropsychopharmacology       Date:  2018-11-02       Impact factor: 7.853

3.  Functional role for cortical-striatal circuitry in modulating alcohol self-administration.

Authors:  Anel A Jaramillo; Patrick A Randall; Spencer Stewart; Brayden Fortino; Kalynn Van Voorhies; Joyce Besheer
Journal:  Neuropharmacology       Date:  2017-11-26       Impact factor: 5.250

4.  Inhibition of mediodorsal thalamus disrupts thalamofrontal connectivity and cognition.

Authors:  Sebastien Parnaudeau; Pia-Kelsey O'Neill; Scott S Bolkan; Ryan D Ward; Atheir I Abbas; Bryan L Roth; Peter D Balsam; Joshua A Gordon; Christoph Kellendonk
Journal:  Neuron       Date:  2013-03-20       Impact factor: 17.173

5.  Designer receptors: therapeutic adjuncts to cell replacement therapy in Parkinson's disease.

Authors:  Elena M Vazey; Gary Aston-Jones
Journal:  J Clin Invest       Date:  2014-06-17       Impact factor: 14.808

6.  DREADDs suppress seizure-like activity in a mouse model of pharmacoresistant epileptic brain tissue.

Authors:  N Avaliani; M Andersson; A H Runegaard; D Woldbye; M Kokaia
Journal:  Gene Ther       Date:  2016-07-14       Impact factor: 5.250

Review 7.  Clozapine plasma level monitoring: current status.

Authors:  T B Cooper
Journal:  Psychiatr Q       Date:  1996

8.  Remote control of induced dopaminergic neurons in parkinsonian rats.

Authors:  Maria Teresa Dell'Anno; Massimiliano Caiazzo; Damiana Leo; Elena Dvoretskova; Lucian Medrihan; Gaia Colasante; Serena Giannelli; Ilda Theka; Giovanni Russo; Liudmila Mus; Gianni Pezzoli; Raul R Gainetdinov; Fabio Benfenati; Stefano Taverna; Alexander Dityatev; Vania Broccoli
Journal:  J Clin Invest       Date:  2014-06-17       Impact factor: 14.808

9.  Chemical Control of Grafted Human PSC-Derived Neurons in a Mouse Model of Parkinson's Disease.

Authors:  Yuejun Chen; Man Xiong; Yi Dong; Alexander Haberman; Jingyuan Cao; Huisheng Liu; Wenhao Zhou; Su-Chun Zhang
Journal:  Cell Stem Cell       Date:  2016-04-28       Impact factor: 24.633

10.  Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance.

Authors:  G Schaber; I Stevens; H J Gaertner; K Dietz; U Breyer-Pfaff
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.